Targeting the Skin Microbiome in Dermatology: Translational Hype or Emerging Therapeutic Modality?

The human skin microbiome is a complex network of microorganisms, including bacteria, fungi, viruses, and archaea, that exist in a mutualistic relationship with the host. These microorganisms play important roles in maintaining skin homeostasis, defense against pathogens, regulation of immune response, and antimicrobial peptide synthesis. Dysbiosis, defined as an imbalance of microbial communities, has been linked to dermatological conditions including atopic dermatitis (AD), acne, psoriasis, and chronic wounds. Despite compelling mechanistic insights, the translation of microbiome science into clinically effective therapies remains inconsistent and prematurely optimistic. Emerging therapeutic strategies aim to restore and modulate the skin microbiome with precision, thereby moving beyond conventional broad-spectrum antimicrobial approaches. These encompass probiotics, prebiotics, synbiotics, live biotherapeutic products (LBPs), bacteriophage therapy, microbiome engineering, postbiotics, microbial consortia treatment, and antimicrobial peptides that selectively target microbial communities instead of eliminating them. While these strategies are biologically plausible and have initial-phase evidence, their clinical stability, reproducibility, and scalability are uncertain. Major limitations include inter-individual variability of microbiomes, transient colonization, methodological limitations in functional profiling, and regulatory uncertainties surrounding them. This review article critically evaluates microbiome-directed dermatologic therapies at the crossroads of real therapeutic potential and translational overextension. The field is not just hype; its clinical application has advanced more rapidly than the supporting evidence base justifies. Progress in this domain requires a shift from descriptive and associative research toward mechanism-driven, precision-based interventions. Such interventions must be validated against robust clinical endpoints. By critically assessing biological plausibility, clinical evidence, and translational barriers, this review provides a balanced perspective on the field and outlines realistic pathways for its evolution into a viable therapeutic paradigm.